These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9886723)

  • 21. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
    Tunny TJ; Ziesak MD; Armstrong R; Klemm SA; Stowasser M; Finn WL; Gordon RD
    J Hypertens Suppl; 1993 Dec; 11(5):S222-3. PubMed ID: 8158355
    [No Abstract]   [Full Text] [Related]  

  • 22. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group.
    Hampton JR; Cowley AJ; Wnuk-Wojnar AM
    Eur Heart J; 1998 Dec; 19(12):1823-8. PubMed ID: 9886725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
    Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
    J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
    Kitaoka H; Takata J; Hitomi N; Furuno T; Seo H; Chikamori T; Doi YL
    Am J Cardiol; 2000 Mar; 85(5):658-60, A10. PubMed ID: 11078286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
    Packer M; Gheorghiade M; Young JB; Costantini PJ; Adams KF; Cody RJ; Smith LK; Van Voorhees L; Gourley LA; Jolly MK
    N Engl J Med; 1993 Jul; 329(1):1-7. PubMed ID: 8505940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man.
    O'Connell JE; Jardine AG; Davies DL; McQueen J; Connell JM
    Clin Sci (Lond); 1993 Jul; 85(1):19-26. PubMed ID: 8149689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
    Littler WA; Sheridan DJ
    Br Heart J; 1995 May; 73(5):428-33. PubMed ID: 7786657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
    Chaitman BR; Ivleva AY; Ujda M; Lenis JH; Toth C; Stieber DM; Reisin LH; Pangerl AM; Friedman JB; Lawrence JH
    Am J Cardiol; 2005 Jun; 95(11):1283-9. PubMed ID: 15904630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome.
    Eizenberg Y; Grossman E; Peleg E; Shabtai Z; Sharabi Y
    J Am Soc Hypertens; 2014 Apr; 8(4):227-31. PubMed ID: 24560177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
    Guazzi M; Agostoni P
    Clin Sci (Lond); 1999 Jan; 96(1):17-22. PubMed ID: 9857102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
    Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E
    Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of long-term ACE-inhibition on pulmonary diffusion and ventilation-perfusion ratio in chronic heart failure: correlation with physical performance].
    Guazzi M; Pontone G; Trevisi N; Lomanto M; Melzi G; Agostoni P
    Ann Ital Med Int; 1998; 13(1):17-23. PubMed ID: 9642838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
    Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.
    Pelliccia F; Borghi A; Ruggeri A; Cianfrocca C; Morgagni GL; Bugiardini R
    Clin Cardiol; 1993 Aug; 16(8):607-12. PubMed ID: 8370193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flosequinan in chronic heart failure: how is exercise capacity improved?
    Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
    Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.